Table 4.
Mean scores of criterions of five DPP-4 inhibitors
| Saxagliptin | Alogliptin | Sitagliptin | linagliptin | Vildagliptin | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Disease severity | 4.00 | 1.26 | 4.00 | 1.26 | 4.00 | 1.26 | 4.00 | 1.26 | 4.00 | 1.26 |
| Size of affected population | 4.33 | 0.52 | 4.33 | 0.52 | 4.33 | 0.52 | 4.33 | 0.52 | 4.33 | 0.52 |
| Unmet needs | 3.50 | 0.55 | 3.50 | 0.55 | 3.50 | 0.55 | 3.50 | 0.55 | 3.50 | 0.55 |
| Comparative effectiveness | 3.50 | 1.64 | 4.33 | 1.03 | 4.67 | 0.52 | 4.33 | 1.03 | 3.67 | 1.51 |
| Comparative safety/tolerability | 0.17 | 0.98 | 0.33 | 0.82 | 0.83 | 0.75 | 0.67 | 1.21 | 0.67 | 0.82 |
| Comparative patient-perceived health / PRO | -0.17 | 0.41 | -0.33 | 0.52 | -0.17 | 0.41 | -0.17 | 0.41 | -0.50 | 0.55 |
| Type of therapeutic benefit | 4.00 | 0.00 | 4.00 | 0.00 | 4.00 | 0.00 | 4.00 | 0.00 | 4.00 | 0.00 |
| Type of preventive benefit | / | / | / | / | / | / | / | / | / | / |
| Comparative cost consequences – cost of intervention | -1.83 | 1.33 | -1.83 | 1.33 | -1.50 | 0.84 | -1.33 | 0.82 | -1.17 | 0.98 |
| Comparative cost consequences – other medical costs | / | / | / | / | / | / | / | / | / | / |
| Comparative cost consequences – non-medical costs | -1.83 | 1.47 | -1.67 | 1.51 | -1.33 | 1.03 | -1.50 | 1.05 | -1.33 | 1.21 |
| Quality of evidence | 3.33 | 0.82 | 3.33 | 0.82 | 3.33 | 0.82 | 3.33 | 0.82 | 3.33 | 0.82 |
| Expert consensus/clinical practice guidelines | 3.67 | 1.51 | 3.67 | 1.51 | 3.67 | 1.51 | 3.67 | 1.51 | 3.67 | 1.51 |